Page last updated: 2024-10-24

NOS2-CD74 complex

Definition

Target type: cellularcomponent

A protein complex comprising nitric oxide synthase 2 and CD74. This stable complex formation is thought to prevent CD74 degradation by caspases. [GOC:BHF, PMID:18003616]

The NOS2-CD74 complex is a dimeric complex formed by the interaction of inducible nitric oxide synthase (NOS2) and the invariant chain (CD74). The complex is localized to the endoplasmic reticulum (ER) membrane and plays a role in the regulation of nitric oxide (NO) production.

**NOS2** is a large, multi-domain enzyme responsible for the production of NO. It is anchored to the ER membrane via its N-terminal domain, which contains a transmembrane region. The catalytic domain of NOS2, located in the ER lumen, is responsible for the conversion of L-arginine to L-citrulline and NO.

**CD74** is a type II transmembrane protein that is primarily known for its role in major histocompatibility complex (MHC) class II antigen presentation. However, CD74 also interacts with NOS2, forming the NOS2-CD74 complex. The N-terminal domain of CD74, located in the ER lumen, interacts with the catalytic domain of NOS2.

The formation of the NOS2-CD74 complex is thought to play a role in regulating NOS2 activity. CD74 may act as a chaperone for NOS2, facilitating its proper folding and assembly. Additionally, the complex may promote the localization of NOS2 to the ER membrane, where it can interact with its substrates.

**Cellular Component:**

The NOS2-CD74 complex is localized to the ER membrane. This localization is essential for the complex to function properly, as it allows NOS2 to access its substrates and interact with other ER-resident proteins. The ER is a network of interconnected membranes that extend throughout the cytoplasm of eukaryotic cells. It plays a critical role in protein synthesis, folding, and modification. The ER membrane is a highly dynamic structure that is constantly changing shape and size, and it is also the site of many important cellular processes, including lipid biosynthesis and calcium storage.

**In summary, the cellular component of the NOS2-CD74 complex is the ER membrane. The complex is localized to the ER membrane due to the presence of transmembrane domains in both NOS2 and CD74. The ER localization of the NOS2-CD74 complex is essential for its function, as it allows the complex to access its substrates and interact with other ER-resident proteins.**'
"

Proteins (1)

ProteinDefinitionTaxonomy
HLA class II histocompatibility antigen gamma chainAn MHC class II histocompatibility antigen gamma chain that is encoded in the genome of human. [PRO:WCB, UniProtKB:P04233]Homo sapiens (human)

Compounds (2)

CompoundDefinitionClassesRoles
crizotinibcrizotinib : A 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine that has R configuration at the chiral centre. The active enantiomer, it acts as a kinase inhibitor and is used for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)

Crizotinib: A piperidine and aminopyridine derivative that acts as an inhibitor of RECEPTOR PROTEIN-TYROSINE KINASES, including ANAPLASTIC LYMPHOMA KINASE (ALK) and HEPATOCYTE GROWTH FACTOR RECEPTOR (HGFR; c-Met). It is used in the treatment of NON-SMALL CELL LUNG CANCER.
3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amineantineoplastic agent;
biomarker;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
pf-06463922lorlatinib : A cyclic ether that is 16,17-dihydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecin-15(10H)-one substituted by methyl groups at positions 2 and 10R, and by cyano, amino and fluoro groups at positions 3, 7 and 12 respectively. It is a small molecule inhibitor of ALK and ROS1 kinase developed by Pfizer for the treatment of ALK-positive non-small cell lung cancer.

lorlatinib: inhibits both anaplastic lymphoma kinase and c-ros oncogene 1 (ROS1) protein
aminopyridine;
aromatic ether;
azamacrocycle;
benzamides;
cyclic ether;
monofluorobenzenes;
nitrile;
organic heterotetracyclic compound;
pyrazoles
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor